2.81

7.57% -0.23

After Hours: 2.77 -0.04 -1.42%

Silexion Therapeutics Corp (SLXN)

Overview News Price History Discussions Forecast

Silexion Therapeutics Corp stock is traded at $2.81, with a volume of 24,535. It is down -7.57% in the last 24 hours and down -3.44% over the past month. Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Previous Close:

$3.04

Open:

$3.04

24h Volume:

24,535

Relative Volume:

0.05

Market Cap:

$8.79M

Revenue:

Net Income/Loss:

$-17.85M

P/E Ratio:

-0.0758

EPS:

-37.0644

Net Cash Flow:

$-13.02M

1W Performance:

-6.95%

1M Performance:

-3.44%

6M Performance:

-78.85%

1Y Performance:

-94.39%

1-Day Range:

$2.76

$3.0461

1-Week Range:

$2.76

$3.13

52-Week Range:

$2.13

$63.45

Silexion Therapeutics Corp Stock (SLXN) Company Profile

Name

Silexion Therapeutics Corp

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

972-8-6286005

Address

12 ABBA HILLEL ROAD, RAMAT GAN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SLXN's Discussions on Twitter

Compare SLXN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLXN Silexion Therapeutics Corp	2.81	9.50M	0	-17.85M	-13.02M	-37.06
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Silexion Therapeutics Corp Stock (SLXN) Latest News

Dec 13, 2025

Bearish Setup: Is Silexion Therapeutics Corp Equity Warrant stock recession proof2025 Momentum Check & AI Forecasted Entry/Exit Points - moha.gov.vn

Dec 13, 2025

Dec 06, 2025

Silexion Shares Decline After Update on German Regulatory Review - MSN

Dec 06, 2025

Dec 05, 2025

Silexion Therapeutics (SLXNW) Stock Analysis Report | Financials & Insights - Benzinga

Dec 05, 2025

How buybacks impact Silexion Therapeutics Corp stock valueProfit Target & Intraday High Probability Setup Alerts - Newser

Dec 05, 2025

Dec 03, 2025

Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment - TipRanks

Dec 03, 2025

Dec 02, 2025

Silexion Therapeutics drops 18%, prices $5M share offering - MSN

Dec 02, 2025

Silexion receives positive feedback from German Health Authority for SIL204 - TipRanks

Dec 02, 2025

Silexion Therapeutics (SLXN) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Silexion stock falls after receiving German regulatory feedback By Investing.com - Investing.com Canada

Dec 02, 2025

Silexion stock falls after receiving German regulatory feedback - Investing.com

Dec 02, 2025

Silexion Therapeutics receives positive feedback from German health authority on design of phase 2/3 clinical trial - marketscreener.com

Dec 02, 2025

Silexion Therapeutics Gains Positive Feedback for SIL204 Trial - TipRanks

Dec 02, 2025

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - GlobeNewswire

Dec 02, 2025

How Silexion Therapeutics Corp Equity Warrant stock reacts to Fed rate cuts2025 Buyback Activity & Weekly Stock Breakout Alerts - Newser

Dec 02, 2025

Nov 28, 2025

Aug Mood: Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Catalysts & Consistent Profit Trade Alerts - moha.gov.vn

Nov 28, 2025

Silexion Completes Toxicology Studies For SIL204; Phase 2/3 Pancreatic Cancer Trial To Begin In Q2 - Nasdaq

Nov 26, 2025

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - marketscreener.com

Nov 26, 2025

Nov 25, 2025

Silexion stock jumps after toxicology studies show no systemic toxicity By Investing.com - Investing.com Canada

Nov 25, 2025

Silexion to begin phase 2/3 pancreatic cancer clinical trial in Q2 2026 - marketscreener.com

Nov 25, 2025

Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026 - TradingView

Nov 25, 2025

Silexion Completes Toxicology Studies for SIL204 Therapy - TipRanks

Nov 25, 2025

Silexion Therapeutics Completes Toxicology Studies for SIL204 - TradingView

Nov 25, 2025

SLXN advances SIL204 toward Phase 2/3 pancreatic cancer study - Stock Titan

Nov 25, 2025

Silexion Therapeutics Reports Successful Toxicology Study Results for SIL204, Paving the Way for Upcoming Phase 2/3 Clinical Trial in Pancreatic Cancer - Quiver Quantitative

Nov 25, 2025

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer - Sahm

Nov 25, 2025

Nov 21, 2025

Can Silexion Therapeutics Corp hit a new high this monthJuly 2025 Closing Moves & Free High Return Stock Watch Alerts - newser.com

Nov 21, 2025

Nov 20, 2025